Clinical Trials
Recruiting
USA
Johns Hopkins University
Peter Calabresi, MD
Sub-Investigators: Johns Ratchford, MD, Christopher Eckstein, MD, Shiv Saidha, MBBCH, Daniel Harrison, MD, Scott Newsome, DO .
Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Relapsing Remitting Multiple Sclerosis
400/1000/10 000 IU vitamin D3 - 6 months
Start Date March 2010
Active, not recruiting
EUROPE, Netherlands
Joost Smolders
Vitamin D3 Supplementation and the T Cell Compartment in Multiple Sclerosis (MS)
Start Date August 2009
.
EUROPE, Norway
Margitta Kampman
Can Vitamin D Supplementation Prevent Bone Loss in Persons With Multiple Sclerosis
20 000 IU cholecalciferol (vitamin D3 per week (or placebo) and 500 mg calcium a day - 96 weeks
Start Date January 2008
.
USA
Vitamin D Status of Pregnant Women and Their Children in Eau Claire, South Carolina
Start Date January 2007
Not yet recruiting
ISRAEL
The Effects of Interferon Beta Combined With Vitamin D on Relapsing Remitting Multiple Sclerosis Patients
Start Date November 2009
.
USA
Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis
Start Date October 2009
Completed
CANADA
Reinhold Vieth
Safety Trial of High Dose Oral Vitamin D3 With Calcium in Multiple Sclerosis (VitD4MS)
Start Date July 2006
Published
Intervention studies
A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis.
Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, Gagne D, D'Souza C, Ursell M, O'Connor P.
Neurology. 2010 Apr 28. [Epub ahead of print]
Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis.
Hiremath GS, Cettomai D, Baynes M, Ratchford JN, Newsome S, Harrison D, Kerr D, Greenberg BM, Calabresi PA.
Mult Scler. 2009 Jun;15(6):735-40. Epub 2009 Apr 21.
Self-prescribed high-dose vitamin D3: effects on biochemical parameters in two men.
Kimball S, Vieth R.
Ann Clin Biochem. 2008 Jan;45(Pt 1):106-10.
Safety of vitamin D3 in adults with multiple sclerosis.
Kimball SM, Ursell MR, O'Connor P, Vieth R.
Am J Clin Nutr. 2007 Sep;86(3):645-51.
A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis.
Wingerchuk DM, Lesaux J, Rice GP, Kremenchutzky M, Ebers GC.
J Neurol Neurosurg Psychiatry. 2005 Sep;76(9):1294-6.
Alfacalcidol treatment in multiple sclerosis.
Achiron A, Barak Y, Miron S, Izhak Y, Faibel M, Edelstein S.
Clin Neuropharmacol. 2003 Mar-Apr;26(2):53. No abstract available.
Cytokine profile in patients with multiple sclerosis following vitamin D supplementation.
Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT.
J Neuroimmunol. 2003 Jan;134(1-2):128-32.
Vitamin Dtreatment of relapsing-remitting multiple sclerosis (RRMS): a MRI based pilot study.
Flemming JO, Hummel AL, Beinlich BR, Borowski BJ, Peebles T, Colburn M, Cook TD, Wendt GJ, DeLuca HL.
Neurology. 2000; 54: A338.
Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D.
Goldberg P, Fleming MC, Picard EH.
Med Hypotheses. 1986 Oct;21(2):193-200.
Observational studies
Immunomodulatory effects of Vitamin D in multiple sclerosis.
Correale J, Ysrraelit MC, Gaitán MI.
Brain. 2009 May;132(Pt 5):1146-60. Epub 2009 Mar 24.
Onset of relapses in multiple sclerosis: the effect of seasonal change in both the northern and southern hemisphere
O. Gray, D. Jolley, K. Gibson, M. Trojano, C. Zwanikken, F. Grand’Maison, P. Duquette, G. Izquierdo, P. Grammond, R. Bergamaschi, T. Petersen, G. Giuliani, R. Taffi, C. Boz, R. Hupperts, M. Rio, V. Van Pesch, J. Lechner-Scott, E. Cristiano, M. Fiol, E. Roullet, D. Poehlau, C. Oreja-Guevara, M. Saladino, F. Verheul, N. Deri, W. Oleschko Arruda, S. Flechter, M. Paine, M. Barnett, A. Savino, J.A. Cabrera-Go´mez, M. Slee, F. Moore, C. Shaw, E. Bacile, T. Petkovska-Boskova, V. Santiago, M. Rutherford, H. Butzkueven.
Mult Scler. 2009; 15: S158 (P532).
Vitamin D status as a predictor of MS outcome following an initial paediatric demyelinating event.
H. Hanwell, R. Vieth, S. Magalhaes, M. McGowan, R.A. Marrie, A. Bar-Or, D. Sadovnick, D. Arnold, B. Banwell, for the Canadian
National Pediatric Demyelinating Diseases Network
Mult Scler. 2009; 15: S40-S41 (P173).
Serum 25-hydroxyvitamin D status as a determinant of multiple sclerosis outcome following an initial demyelinating event in
children.
Heather E. Hanwell, Reinhold Vieth, Amit Bar-Or, Dessa Sadovnick, Doug Arnold, Brenda Banwell, for the Canadian
Pediatric Demyelinating Disease Study Group.
Mult Scler. 2008; 14: S6 (4).
Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women.
Kragt J, van Amerongen B, Killestein J, Dijkstra C, Uitdehaag B, Polman Ch, Lips P.
Mult Scler. 2009 Jan;15(1):9-15. Epub 2008 Aug 13.
25-hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis.
Holmøy T, Moen SM, Gundersen TA, Holick MF, Fainardi E, Castellazzi M, Casetta I.
Mult Scler. 2009 Nov;15(11):1280-5. Epub 2009 Oct 6.
Monthly ambient sunlight, infections and relapse rates in multiple sclerosis.
Tremlett H, van der Mei IA, Pittas F, Blizzard L, Paley G, Mesaros D, Woodbaker R, Nunez M, Dwyer T, Taylor BV, Ponsonby AL.
Neuroepidemiology. 2008;31(4):271-9. Epub 2008 Oct 30.
Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis.
Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R.
Mult Scler. 2008 Nov;14(9):1220-4. Epub 2008 Jul 24.
A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis.
Soilu-Hänninen M, Laaksonen M, Laitinen I, Erälinna JP, Lilius EM, Mononen I.
J Neurol Neurosurg Psychiatry. 2008 Feb;79(2):152-7. Epub 2007 Jun 19.
Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia.
van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Taylor BV, Kilpatrick T, Butzkueven H, McMichael AJ.
J Neurol. 2007 May;254(5):581-90. Epub 2007 Apr 11.
25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis.
Soilu-Hänninen M, Airas L, Mononen I, Heikkilä A, Viljanen M, Hänninen A.
Mult Scler. 2005 Jun;11(3):266-71.
Multiple sclerosis and vitamin D: an update.
VanAmerongen BM, Dijkstra CD, Lips P, Polman CH.
Eur J Clin Nutr. 2004 Aug;58(8):1095-109. Review.
Risk of bone loss in men with multiple sclerosis.
Weinstock-Guttman B, Gallagher E, Baier M, Green L, Feichter J, Patrick K, Miller C, Wrest K, Ramanathan M.
Mult Scler. 2004 Apr;10(2):170-5.
Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis.
Embry AF, Snowdon LR, Vieth R.
Ann Neurol. 2000 Aug;48(2):271-2. No abstract available.
Fracture history and bone loss in patients with MS.
Cosman F, Nieves J, Komar L, Ferrer G, Herbert J, Formica C, Shen V, Lindsay R.
Neurology. 1998 Oct;51(4):1161-5.
High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis.
Nieves J, Cosman F, Herbert J, Shen V, Lindsay R.
Neurology. 1994 Sep;44(9):1687-92.
